GlobeNewswire: Cara Therapeutics, Inc. Contains the last 10 of 227 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:12:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/07/2842091/0/en/Cara-Therapeutics-to-Host-Notalgia-Paresthetica-NP-Virtual-KOL-Event-on-Wednesday-March-27-2024.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 20242024-03-07T12:00:00Z<![CDATA[STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT.]]>https://www.globenewswire.com/news-release/2024/03/04/2839952/0/en/Cara-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results2024-03-04T21:01:00Z<![CDATA[–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)–]]>https://www.globenewswire.com/news-release/2024/02/12/2827845/0/en/Cara-Therapeutics-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-4-2024.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 20242024-02-12T21:01:00Z<![CDATA[STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2024/01/22/2812893/0/en/Cara-Therapeutics-Prioritizes-Late-Stage-Notalgia-Paresthetica-Program-and-Extends-Cash-Runway-into-2026.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 20262024-01-22T12:00:00Z<![CDATA[– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need –]]>https://www.globenewswire.com/news-release/2023/12/18/2797670/0/en/Cara-Therapeutics-Announces-Outcome-from-Dose-Finding-Part-A-of-KIND-1-Study-Evaluating-Oral-Difelikefalin-for-Moderate-to-Severe-Pruritus-in-Patients-with-Atopic-Dermatitis.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis2023-12-18T12:00:00Z<![CDATA[– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis –]]>https://www.globenewswire.com/news-release/2023/11/13/2779412/0/en/Cara-Therapeutics-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics Reports Third Quarter 2023 Financial Results2023-11-13T21:01:00Z<![CDATA[– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 –]]>https://www.globenewswire.com/news-release/2023/11/02/2772132/0/en/Cara-Therapeutics-Announces-up-to-40-0-Million-Non-Dilutive-Financing-Agreement-with-HealthCare-Royalty.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty2023-11-02T11:00:45Z<![CDATA[Transaction supports progression of late-stage oral difelikefalin clinical programs]]>https://www.globenewswire.com/news-release/2023/10/23/2764571/0/en/Cara-Therapeutics-to-Announce-Third-Quarter-2023-Financial-Results-on-November-13-2023.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 20232023-10-23T11:00:00Z<![CDATA[STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 13, 2023, at 4:30 p.m. ET to report third quarter 2023 financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2023/09/25/2748511/0/en/Cara-Therapeutics-Announces-Approval-of-KORSUVA-IV-Injection-Syringe-in-Japan-for-the-Treatment-of-Pruritus-in-Hemodialysis-Patients.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients2023-09-25T11:00:32Z<![CDATA[Approval triggers $1.5 million milestone payment to Cara Approval triggers $1.5 million milestone payment to Cara]]>https://www.globenewswire.com/news-release/2023/09/05/2737164/0/en/Cara-Therapeutics-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=20909Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference2023-09-05T11:00:00Z<![CDATA[STAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:00 a.m. EDT in New York, NY.]]>